| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Uterine Cervical Neoplasms | 47 | 2023 | 1913 | 4.000 |
Why?
|
| Spirituality | 10 | 2014 | 129 | 2.620 |
Why?
|
| Papillomavirus Infections | 14 | 2024 | 1014 | 2.520 |
Why?
|
| Genital Neoplasms, Female | 19 | 2021 | 791 | 2.470 |
Why?
|
| Papillomavirus Vaccines | 11 | 2024 | 196 | 2.460 |
Why?
|
| Endometrial Neoplasms | 29 | 2023 | 1389 | 2.160 |
Why?
|
| Uterine Neoplasms | 13 | 2018 | 579 | 1.620 |
Why?
|
| Ovarian Neoplasms | 26 | 2024 | 4797 | 1.600 |
Why?
|
| Students, Medical | 3 | 2019 | 421 | 1.320 |
Why?
|
| Internal-External Control | 4 | 2017 | 108 | 1.260 |
Why?
|
| Health Knowledge, Attitudes, Practice | 5 | 2019 | 1232 | 1.220 |
Why?
|
| Endometrial Hyperplasia | 4 | 2023 | 124 | 1.170 |
Why?
|
| Papillomaviridae | 6 | 2019 | 645 | 1.160 |
Why?
|
| Vaccination | 9 | 2024 | 1156 | 1.120 |
Why?
|
| Patient Acceptance of Health Care | 4 | 2017 | 605 | 1.110 |
Why?
|
| Carcinosarcoma | 8 | 2021 | 149 | 1.060 |
Why?
|
| Insurance, Health | 3 | 2018 | 263 | 1.040 |
Why?
|
| Vulvar Neoplasms | 4 | 2022 | 236 | 1.030 |
Why?
|
| Religion | 5 | 2013 | 95 | 0.990 |
Why?
|
| Medically Underserved Area | 3 | 2015 | 122 | 0.970 |
Why?
|
| Female | 152 | 2024 | 149288 | 0.900 |
Why?
|
| Paclitaxel | 16 | 2023 | 2099 | 0.890 |
Why?
|
| Granulosa Cell Tumor | 4 | 2024 | 81 | 0.860 |
Why?
|
| Health Services Accessibility | 5 | 2015 | 813 | 0.840 |
Why?
|
| Health Care Costs | 7 | 2019 | 700 | 0.810 |
Why?
|
| Carcinoma, Endometrioid | 8 | 2020 | 329 | 0.810 |
Why?
|
| Terminal Care | 8 | 2019 | 465 | 0.800 |
Why?
|
| Middle Aged | 105 | 2024 | 90460 | 0.780 |
Why?
|
| Bariatric Surgery | 1 | 2023 | 124 | 0.770 |
Why?
|
| Medical Oncology | 8 | 2024 | 1464 | 0.760 |
Why?
|
| Vaginal Neoplasms | 3 | 2020 | 155 | 0.740 |
Why?
|
| Holistic Health | 2 | 2013 | 13 | 0.740 |
Why?
|
| Adult | 91 | 2024 | 81933 | 0.730 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 26 | 2023 | 16612 | 0.730 |
Why?
|
| Texas | 19 | 2024 | 6440 | 0.730 |
Why?
|
| Attitude of Health Personnel | 4 | 2013 | 920 | 0.720 |
Why?
|
| Physician-Patient Relations | 7 | 2013 | 738 | 0.720 |
Why?
|
| Quality of Life | 22 | 2023 | 4755 | 0.690 |
Why?
|
| Education, Medical, Undergraduate | 2 | 2019 | 201 | 0.680 |
Why?
|
| Gynecology | 5 | 2018 | 235 | 0.670 |
Why?
|
| Humans | 160 | 2024 | 272087 | 0.670 |
Why?
|
| Healthcare Disparities | 4 | 2019 | 653 | 0.650 |
Why?
|
| Anxiety | 8 | 2023 | 1230 | 0.650 |
Why?
|
| Propranolol | 1 | 2019 | 160 | 0.640 |
Why?
|
| Adaptation, Psychological | 5 | 2014 | 787 | 0.640 |
Why?
|
| Hormone Antagonists | 2 | 2009 | 122 | 0.610 |
Why?
|
| Mifepristone | 2 | 2009 | 196 | 0.610 |
Why?
|
| Peer Group | 1 | 2019 | 135 | 0.610 |
Why?
|
| Aged | 78 | 2024 | 73517 | 0.570 |
Why?
|
| Health Promotion | 2 | 2024 | 510 | 0.550 |
Why?
|
| Practice Patterns, Physicians' | 3 | 2011 | 1324 | 0.540 |
Why?
|
| Neoplasm Recurrence, Local | 14 | 2024 | 10365 | 0.530 |
Why?
|
| Palliative Care | 4 | 2015 | 2161 | 0.510 |
Why?
|
| Self-Examination | 1 | 2015 | 12 | 0.510 |
Why?
|
| Faculty, Medical | 1 | 2019 | 308 | 0.510 |
Why?
|
| Hysterectomy | 8 | 2021 | 649 | 0.500 |
Why?
|
| Neoplasm Staging | 30 | 2020 | 13993 | 0.490 |
Why?
|
| Gastrointestinal Microbiome | 5 | 2022 | 968 | 0.490 |
Why?
|
| Health Expenditures | 1 | 2017 | 201 | 0.490 |
Why?
|
| Mind-Body Therapies | 1 | 2014 | 29 | 0.480 |
Why?
|
| Medicaid | 3 | 2019 | 307 | 0.480 |
Why?
|
| Advance Care Planning | 4 | 2017 | 93 | 0.470 |
Why?
|
| Sexual Dysfunction, Physiological | 1 | 2015 | 143 | 0.460 |
Why?
|
| Cancer Survivors | 3 | 2020 | 744 | 0.450 |
Why?
|
| Vulnerable Populations | 1 | 2015 | 188 | 0.450 |
Why?
|
| Mental Health | 1 | 2017 | 416 | 0.440 |
Why?
|
| Symptom Assessment | 1 | 2015 | 274 | 0.440 |
Why?
|
| Physician's Role | 2 | 2013 | 232 | 0.430 |
Why?
|
| Integrative Oncology | 2 | 2024 | 36 | 0.430 |
Why?
|
| Surveys and Questionnaires | 11 | 2019 | 5935 | 0.430 |
Why?
|
| Poverty | 2 | 2018 | 478 | 0.430 |
Why?
|
| Alphapapillomavirus | 3 | 2022 | 174 | 0.430 |
Why?
|
| Young Adult | 31 | 2024 | 22142 | 0.430 |
Why?
|
| Receptors, Adrenergic | 1 | 2013 | 54 | 0.420 |
Why?
|
| Attitude to Death | 4 | 2016 | 102 | 0.410 |
Why?
|
| Pastoral Care | 1 | 2011 | 7 | 0.400 |
Why?
|
| Cystadenocarcinoma, Papillary | 5 | 2005 | 83 | 0.400 |
Why?
|
| Clinical Competence | 2 | 2019 | 1327 | 0.380 |
Why?
|
| Religion and Medicine | 2 | 2011 | 46 | 0.380 |
Why?
|
| Topotecan | 7 | 2023 | 248 | 0.380 |
Why?
|
| Cystadenoma, Serous | 1 | 2011 | 31 | 0.370 |
Why?
|
| Ovarian Cysts | 1 | 2011 | 41 | 0.370 |
Why?
|
| Albumins | 1 | 2012 | 267 | 0.370 |
Why?
|
| Cisplatin | 16 | 2023 | 2497 | 0.370 |
Why?
|
| Neoplasms, Glandular and Epithelial | 1 | 2015 | 522 | 0.360 |
Why?
|
| Neoplasms | 10 | 2024 | 15930 | 0.350 |
Why?
|
| Cyclin-Dependent Kinase Inhibitor p16 | 2 | 2010 | 507 | 0.350 |
Why?
|
| Lymph Node Excision | 6 | 2018 | 2054 | 0.350 |
Why?
|
| Cyclins | 3 | 2001 | 470 | 0.340 |
Why?
|
| Sarcoma, Endometrial Stromal | 1 | 2009 | 15 | 0.340 |
Why?
|
| Aged, 80 and over | 35 | 2023 | 31066 | 0.330 |
Why?
|
| Chemotherapy, Adjuvant | 11 | 2019 | 3980 | 0.330 |
Why?
|
| Intrauterine Devices, Medicated | 2 | 2020 | 38 | 0.330 |
Why?
|
| Abdomen | 1 | 2011 | 348 | 0.320 |
Why?
|
| Primary Health Care | 1 | 2015 | 845 | 0.320 |
Why?
|
| Levonorgestrel | 2 | 2020 | 53 | 0.320 |
Why?
|
| Neoplasms, Unknown Primary | 1 | 2010 | 199 | 0.320 |
Why?
|
| Disease Management | 2 | 2020 | 1113 | 0.310 |
Why?
|
| Carboplatin | 6 | 2024 | 879 | 0.310 |
Why?
|
| Decision Making | 3 | 2014 | 1247 | 0.300 |
Why?
|
| Gestational Trophoblastic Disease | 2 | 2018 | 24 | 0.300 |
Why?
|
| Retroperitoneal Neoplasms | 1 | 2010 | 299 | 0.300 |
Why?
|
| Neoplasms, Squamous Cell | 1 | 2008 | 85 | 0.300 |
Why?
|
| Antineoplastic Agents | 12 | 2021 | 14653 | 0.290 |
Why?
|
| Aorta | 2 | 2010 | 684 | 0.290 |
Why?
|
| Receptor, Platelet-Derived Growth Factor beta | 2 | 2005 | 154 | 0.290 |
Why?
|
| Neurofeedback | 2 | 2018 | 20 | 0.290 |
Why?
|
| Burnout, Professional | 1 | 2011 | 227 | 0.290 |
Why?
|
| Nausea | 3 | 2020 | 540 | 0.290 |
Why?
|
| Mixed Tumor, Mullerian | 2 | 2004 | 38 | 0.280 |
Why?
|
| Tamoxifen | 3 | 2002 | 906 | 0.280 |
Why?
|
| Adrenergic beta-Antagonists | 3 | 2019 | 330 | 0.270 |
Why?
|
| Prospective Studies | 13 | 2024 | 13410 | 0.270 |
Why?
|
| Adenocarcinoma | 10 | 2021 | 7976 | 0.270 |
Why?
|
| Critical Illness | 1 | 2011 | 743 | 0.270 |
Why?
|
| Proto-Oncogene Proteins c-abl | 2 | 2005 | 83 | 0.260 |
Why?
|
| Pelvic Exenteration | 2 | 2018 | 112 | 0.260 |
Why?
|
| Retrospective Studies | 32 | 2024 | 39831 | 0.260 |
Why?
|
| Health Status Disparities | 1 | 2009 | 320 | 0.260 |
Why?
|
| Physicians | 2 | 2013 | 870 | 0.260 |
Why?
|
| Fallopian Tube Neoplasms | 3 | 2018 | 155 | 0.260 |
Why?
|
| Ki-67 Antigen | 5 | 2021 | 685 | 0.250 |
Why?
|
| Positron-Emission Tomography | 2 | 2012 | 2198 | 0.250 |
Why?
|
| Cross-Sectional Studies | 5 | 2019 | 4513 | 0.250 |
Why?
|
| Carcinoma in Situ | 2 | 2022 | 496 | 0.250 |
Why?
|
| United States | 14 | 2022 | 16066 | 0.240 |
Why?
|
| Chemoradiotherapy | 4 | 2022 | 2029 | 0.240 |
Why?
|
| Cystadenocarcinoma, Serous | 4 | 2019 | 499 | 0.230 |
Why?
|
| Lymphatic Metastasis | 4 | 2019 | 4968 | 0.230 |
Why?
|
| Bevacizumab | 5 | 2023 | 957 | 0.230 |
Why?
|
| Hospices | 3 | 2019 | 50 | 0.230 |
Why?
|
| Psilocybin | 1 | 2023 | 4 | 0.230 |
Why?
|
| Proto-Oncogene Proteins c-kit | 2 | 2005 | 490 | 0.230 |
Why?
|
| Depression | 5 | 2023 | 1737 | 0.220 |
Why?
|
| Peripheral Nervous System Diseases | 2 | 2018 | 408 | 0.220 |
Why?
|
| Magnesium | 1 | 2024 | 172 | 0.220 |
Why?
|
| Paget Disease, Extramammary | 1 | 2003 | 54 | 0.220 |
Why?
|
| Deoxycytidine | 6 | 2010 | 1378 | 0.220 |
Why?
|
| Diagnostic Errors | 1 | 2008 | 532 | 0.220 |
Why?
|
| Laparoscopy | 2 | 2021 | 1298 | 0.220 |
Why?
|
| Antineoplastic Agents, Phytogenic | 2 | 2013 | 895 | 0.210 |
Why?
|
| Neoplasms, Multiple Primary | 1 | 2006 | 564 | 0.210 |
Why?
|
| Meditation | 1 | 2024 | 78 | 0.210 |
Why?
|
| Infusions, Intravenous | 4 | 2019 | 1442 | 0.210 |
Why?
|
| Yoga | 1 | 2024 | 88 | 0.210 |
Why?
|
| Integrative Medicine | 1 | 2023 | 41 | 0.210 |
Why?
|
| Efficiency | 1 | 2003 | 94 | 0.210 |
Why?
|
| Choriocarcinoma | 1 | 2002 | 49 | 0.200 |
Why?
|
| Social Support | 3 | 2013 | 590 | 0.200 |
Why?
|
| Complementary Therapies | 1 | 2023 | 118 | 0.200 |
Why?
|
| Uterine Cervical Dysplasia | 2 | 2023 | 222 | 0.200 |
Why?
|
| Cohort Studies | 10 | 2024 | 9500 | 0.200 |
Why?
|
| Carcinoma, Squamous Cell | 8 | 2021 | 5603 | 0.200 |
Why?
|
| Male | 20 | 2024 | 129088 | 0.190 |
Why?
|
| Tumor Suppressor Protein p53 | 5 | 2021 | 3671 | 0.190 |
Why?
|
| Oncogene Proteins, Viral | 1 | 2022 | 148 | 0.190 |
Why?
|
| Endometrium | 3 | 2016 | 469 | 0.190 |
Why?
|
| Conservative Treatment | 1 | 2021 | 66 | 0.190 |
Why?
|
| Patient Preference | 2 | 2014 | 225 | 0.190 |
Why?
|
| Apoptosis | 4 | 2016 | 7837 | 0.190 |
Why?
|
| Trophoblasts | 1 | 2002 | 151 | 0.190 |
Why?
|
| Medically Uninsured | 2 | 2015 | 106 | 0.180 |
Why?
|
| Ovary | 2 | 2011 | 701 | 0.180 |
Why?
|
| Mentors | 1 | 2003 | 203 | 0.180 |
Why?
|
| Vomiting | 2 | 2020 | 361 | 0.180 |
Why?
|
| Granisetron | 1 | 2020 | 8 | 0.180 |
Why?
|
| Treatment Outcome | 21 | 2021 | 33909 | 0.180 |
Why?
|
| Wolffian Ducts | 1 | 2020 | 24 | 0.180 |
Why?
|
| Ondansetron | 1 | 2020 | 39 | 0.180 |
Why?
|
| Biological Products | 1 | 2024 | 319 | 0.170 |
Why?
|
| Peritoneal Neoplasms | 3 | 2018 | 857 | 0.170 |
Why?
|
| Feasibility Studies | 4 | 2021 | 2355 | 0.170 |
Why?
|
| Postoperative Care | 1 | 2003 | 731 | 0.170 |
Why?
|
| Social Class | 4 | 2011 | 322 | 0.170 |
Why?
|
| Immunohistochemistry | 10 | 2018 | 7828 | 0.170 |
Why?
|
| Pilot Projects | 3 | 2019 | 2867 | 0.170 |
Why?
|
| Antibodies, Monoclonal, Humanized | 4 | 2021 | 3395 | 0.170 |
Why?
|
| Cytoreduction Surgical Procedures | 1 | 2024 | 510 | 0.170 |
Why?
|
| Renal Tubular Transport, Inborn Errors | 1 | 2019 | 11 | 0.170 |
Why?
|
| Hypercalciuria | 1 | 2019 | 14 | 0.170 |
Why?
|
| Nephrocalcinosis | 1 | 2019 | 16 | 0.170 |
Why?
|
| Fatigue | 4 | 2015 | 1281 | 0.170 |
Why?
|
| Proto-Oncogene Proteins c-bcl-2 | 3 | 2007 | 1547 | 0.160 |
Why?
|
| Withholding Treatment | 1 | 2020 | 155 | 0.160 |
Why?
|
| Antiemetics | 1 | 2020 | 123 | 0.160 |
Why?
|
| Weight Loss | 1 | 2023 | 639 | 0.160 |
Why?
|
| Efficiency, Organizational | 1 | 2019 | 94 | 0.160 |
Why?
|
| Advance Directives | 2 | 2016 | 90 | 0.160 |
Why?
|
| Patient Satisfaction | 3 | 2018 | 916 | 0.160 |
Why?
|
| Health Plan Implementation | 1 | 2019 | 90 | 0.160 |
Why?
|
| Condylomata Acuminata | 1 | 2018 | 32 | 0.160 |
Why?
|
| Cancer Care Facilities | 3 | 2019 | 908 | 0.160 |
Why?
|
| Patient Reported Outcome Measures | 3 | 2020 | 864 | 0.160 |
Why?
|
| Safety | 1 | 2020 | 465 | 0.150 |
Why?
|
| Polyps | 1 | 1999 | 82 | 0.150 |
Why?
|
| Meigs Syndrome | 1 | 1997 | 1 | 0.150 |
Why?
|
| Estrogen Antagonists | 1 | 1999 | 219 | 0.150 |
Why?
|
| Carcinoma | 3 | 2020 | 2623 | 0.150 |
Why?
|
| Frozen Sections | 1 | 2018 | 118 | 0.150 |
Why?
|
| Psychotherapy | 2 | 2023 | 246 | 0.150 |
Why?
|
| Truth Disclosure | 2 | 2013 | 180 | 0.150 |
Why?
|
| Linear Models | 2 | 2018 | 1102 | 0.140 |
Why?
|
| Data Collection | 3 | 2013 | 624 | 0.140 |
Why?
|
| Microbiota | 1 | 2023 | 545 | 0.140 |
Why?
|
| Survival Rate | 10 | 2024 | 12534 | 0.140 |
Why?
|
| Emergency Service, Hospital | 2 | 2015 | 1243 | 0.140 |
Why?
|
| Leukocytes | 1 | 2019 | 426 | 0.140 |
Why?
|
| Pathology | 1 | 2018 | 108 | 0.140 |
Why?
|
| Pelvic Inflammatory Disease | 1 | 1996 | 10 | 0.140 |
Why?
|
| Gastrointestinal Tract | 1 | 2020 | 326 | 0.140 |
Why?
|
| Medical Futility | 1 | 2017 | 56 | 0.140 |
Why?
|
| Vaginal Douching | 1 | 2016 | 5 | 0.140 |
Why?
|
| Time Factors | 8 | 2021 | 13139 | 0.140 |
Why?
|
| Longitudinal Studies | 2 | 2019 | 2058 | 0.140 |
Why?
|
| Smoking Cessation | 1 | 2023 | 768 | 0.140 |
Why?
|
| Costs and Cost Analysis | 1 | 2017 | 311 | 0.140 |
Why?
|
| Education, Medical, Graduate | 1 | 2003 | 700 | 0.140 |
Why?
|
| Cell Division | 2 | 2001 | 2711 | 0.130 |
Why?
|
| Intestines | 1 | 2021 | 740 | 0.130 |
Why?
|
| Medicare | 4 | 2019 | 935 | 0.130 |
Why?
|
| Prognosis | 15 | 2022 | 22555 | 0.130 |
Why?
|
| Obesity | 3 | 2023 | 2958 | 0.130 |
Why?
|
| Genetic Therapy | 2 | 2004 | 1739 | 0.130 |
Why?
|
| Automobiles | 1 | 2015 | 10 | 0.130 |
Why?
|
| Kaplan-Meier Estimate | 7 | 2021 | 6270 | 0.130 |
Why?
|
| Survivors | 2 | 2023 | 1025 | 0.130 |
Why?
|
| Tomography, X-Ray Computed | 2 | 2010 | 7792 | 0.130 |
Why?
|
| Receptors, Progesterone | 3 | 2009 | 1649 | 0.130 |
Why?
|
| Disease-Free Survival | 8 | 2018 | 10259 | 0.130 |
Why?
|
| Educational Measurement | 1 | 2018 | 398 | 0.130 |
Why?
|
| Neoplastic Cells, Circulating | 1 | 2020 | 640 | 0.130 |
Why?
|
| Survival Analysis | 8 | 2023 | 9326 | 0.130 |
Why?
|
| Gene Expression | 3 | 2020 | 3690 | 0.130 |
Why?
|
| Psychometrics | 2 | 2017 | 964 | 0.130 |
Why?
|
| Health Personnel | 2 | 2020 | 654 | 0.130 |
Why?
|
| Safety-net Providers | 1 | 2015 | 55 | 0.130 |
Why?
|
| Radiotherapy, Adjuvant | 6 | 2018 | 2270 | 0.120 |
Why?
|
| Sex Factors | 2 | 2018 | 2208 | 0.120 |
Why?
|
| Ifosfamide | 2 | 2007 | 357 | 0.120 |
Why?
|
| Abscess | 1 | 1996 | 192 | 0.120 |
Why?
|
| Gene Products, env | 1 | 2014 | 36 | 0.120 |
Why?
|
| Body Image | 2 | 2018 | 123 | 0.120 |
Why?
|
| Intestinal Obstruction | 1 | 2017 | 224 | 0.120 |
Why?
|
| Leiomyosarcoma | 1 | 2016 | 255 | 0.120 |
Why?
|
| Registries | 4 | 2024 | 2253 | 0.120 |
Why?
|
| Endogenous Retroviruses | 1 | 2014 | 43 | 0.120 |
Why?
|
| Anorexia | 1 | 2015 | 147 | 0.120 |
Why?
|
| Documentation | 1 | 2016 | 216 | 0.120 |
Why?
|
| Sarcoma | 1 | 2005 | 1842 | 0.120 |
Why?
|
| Constipation | 1 | 2015 | 184 | 0.120 |
Why?
|
| Health Literacy | 1 | 2015 | 116 | 0.120 |
Why?
|
| Delayed Diagnosis | 1 | 2015 | 152 | 0.120 |
Why?
|
| Pain | 2 | 2015 | 1697 | 0.120 |
Why?
|
| Fear | 1 | 2015 | 259 | 0.110 |
Why?
|
| Drainage | 1 | 1996 | 448 | 0.110 |
Why?
|
| Parents | 2 | 2020 | 1072 | 0.110 |
Why?
|
| Neoadjuvant Therapy | 2 | 2019 | 5213 | 0.110 |
Why?
|
| Sleep Initiation and Maintenance Disorders | 1 | 2015 | 141 | 0.110 |
Why?
|
| Angiogenesis Inhibitors | 3 | 2020 | 1265 | 0.110 |
Why?
|
| Stromal Cells | 1 | 1997 | 835 | 0.110 |
Why?
|
| TOR Serine-Threonine Kinases | 2 | 2010 | 1575 | 0.110 |
Why?
|
| Neoplasm Grading | 4 | 2020 | 1827 | 0.110 |
Why?
|
| Disease Progression | 7 | 2023 | 6911 | 0.110 |
Why?
|
| Genes, p53 | 3 | 2004 | 1146 | 0.110 |
Why?
|
| Antineoplastic Agents, Hormonal | 1 | 1998 | 848 | 0.110 |
Why?
|
| Specimen Handling | 1 | 2015 | 314 | 0.110 |
Why?
|
| Adolescent | 10 | 2024 | 32730 | 0.110 |
Why?
|
| Ambulatory Care | 1 | 2017 | 607 | 0.110 |
Why?
|
| Lymph Nodes | 3 | 2018 | 3080 | 0.110 |
Why?
|
| Cytokines | 2 | 2019 | 2841 | 0.110 |
Why?
|
| Culture | 1 | 2013 | 105 | 0.110 |
Why?
|
| Hospice Care | 1 | 2014 | 161 | 0.100 |
Why?
|
| Metformin | 1 | 2016 | 395 | 0.100 |
Why?
|
| Models, Statistical | 1 | 2018 | 1190 | 0.100 |
Why?
|
| Cost of Illness | 2 | 2018 | 505 | 0.100 |
Why?
|
| Blood Transfusion | 1 | 2015 | 583 | 0.100 |
Why?
|
| Neoplasms, Radiation-Induced | 2 | 2006 | 404 | 0.100 |
Why?
|
| Hypoglycemic Agents | 1 | 2016 | 620 | 0.100 |
Why?
|
| Combined Modality Therapy | 4 | 2014 | 9046 | 0.100 |
Why?
|
| Oropharyngeal Neoplasms | 1 | 2021 | 1159 | 0.100 |
Why?
|
| Aorta, Abdominal | 1 | 2012 | 151 | 0.100 |
Why?
|
| Quality Improvement | 1 | 2019 | 918 | 0.100 |
Why?
|
| Amniocentesis | 1 | 2011 | 83 | 0.100 |
Why?
|
| Suicide, Assisted | 1 | 2011 | 21 | 0.090 |
Why?
|
| Phospholipase D | 1 | 2010 | 27 | 0.090 |
Why?
|
| Health Status | 1 | 2014 | 634 | 0.090 |
Why?
|
| Ethics Consultation | 1 | 2011 | 36 | 0.090 |
Why?
|
| Pelvis | 1 | 2012 | 384 | 0.090 |
Why?
|
| Genetic Testing | 1 | 2018 | 1699 | 0.090 |
Why?
|
| Recurrence | 4 | 2015 | 4887 | 0.090 |
Why?
|
| Drug Administration Schedule | 5 | 2017 | 3543 | 0.090 |
Why?
|
| Drug-Related Side Effects and Adverse Reactions | 1 | 2015 | 630 | 0.090 |
Why?
|
| Inhibitory Concentration 50 | 2 | 2007 | 286 | 0.090 |
Why?
|
| Cyclin-Dependent Kinase Inhibitor p21 | 3 | 2001 | 541 | 0.090 |
Why?
|
| Laparotomy | 1 | 2011 | 231 | 0.090 |
Why?
|
| Enzyme Inhibitors | 3 | 2004 | 1966 | 0.080 |
Why?
|
| Early Detection of Cancer | 1 | 2018 | 1342 | 0.080 |
Why?
|
| T-Lymphocytes, Cytotoxic | 1 | 2014 | 1020 | 0.080 |
Why?
|
| Social Media | 1 | 2013 | 211 | 0.080 |
Why?
|
| Marital Status | 1 | 2009 | 93 | 0.080 |
Why?
|
| Education, Medical, Continuing | 1 | 2011 | 234 | 0.080 |
Why?
|
| Hypotension | 1 | 2011 | 237 | 0.080 |
Why?
|
| Adenocarcinoma, Clear Cell | 2 | 2006 | 183 | 0.080 |
Why?
|
| Brachytherapy | 2 | 2013 | 1005 | 0.080 |
Why?
|
| Biomarkers, Tumor | 6 | 2020 | 10750 | 0.080 |
Why?
|
| Salvage Therapy | 1 | 2017 | 2119 | 0.080 |
Why?
|
| Referral and Consultation | 1 | 2014 | 941 | 0.080 |
Why?
|
| State Health Plans | 1 | 2008 | 8 | 0.080 |
Why?
|
| Stress, Psychological | 1 | 2015 | 1039 | 0.080 |
Why?
|
| Fluorodeoxyglucose F18 | 2 | 2012 | 1260 | 0.080 |
Why?
|
| Risk Factors | 7 | 2020 | 18051 | 0.080 |
Why?
|
| Severity of Illness Index | 3 | 2015 | 4400 | 0.080 |
Why?
|
| Hospitalization | 1 | 2017 | 2203 | 0.080 |
Why?
|
| Ovariectomy | 3 | 2013 | 372 | 0.080 |
Why?
|
| Cyclooxygenase 2 | 2 | 2007 | 498 | 0.080 |
Why?
|
| Conization | 2 | 2021 | 38 | 0.080 |
Why?
|
| Antimetabolites, Antineoplastic | 2 | 2005 | 1351 | 0.080 |
Why?
|
| Taxoids | 2 | 2017 | 1010 | 0.070 |
Why?
|
| Child | 3 | 2019 | 30559 | 0.070 |
Why?
|
| Randomized Controlled Trials as Topic | 2 | 2024 | 2681 | 0.070 |
Why?
|
| Neoplasms, Hormone-Dependent | 1 | 2009 | 353 | 0.070 |
Why?
|
| Urban Population | 1 | 2009 | 281 | 0.070 |
Why?
|
| Reproducibility of Results | 4 | 2021 | 6210 | 0.070 |
Why?
|
| Carcinoma, Neuroendocrine | 1 | 2013 | 741 | 0.070 |
Why?
|
| Health Care Surveys | 2 | 2008 | 425 | 0.070 |
Why?
|
| Tumor Microenvironment | 3 | 2023 | 3026 | 0.070 |
Why?
|
| Follow-Up Studies | 6 | 2019 | 15279 | 0.070 |
Why?
|
| Receptors, Estrogen | 2 | 2005 | 2268 | 0.070 |
Why?
|
| Empathy | 1 | 2007 | 103 | 0.070 |
Why?
|
| Hematologic Neoplasms | 1 | 2018 | 1950 | 0.070 |
Why?
|
| Receptors, Steroid | 1 | 2007 | 356 | 0.070 |
Why?
|
| Quinazolines | 2 | 2008 | 953 | 0.070 |
Why?
|
| Piperazines | 2 | 2005 | 2152 | 0.070 |
Why?
|
| Sirolimus | 1 | 2010 | 833 | 0.070 |
Why?
|
| Nuclear Family | 1 | 2005 | 68 | 0.060 |
Why?
|
| Fatal Outcome | 1 | 2008 | 835 | 0.060 |
Why?
|
| Lymphocytes, Tumor-Infiltrating | 2 | 2021 | 1015 | 0.060 |
Why?
|
| Clinical Trials, Phase III as Topic | 1 | 2007 | 499 | 0.060 |
Why?
|
| Sex Cord-Gonadal Stromal Tumors | 1 | 2005 | 38 | 0.060 |
Why?
|
| Insulin Resistance | 1 | 2011 | 748 | 0.060 |
Why?
|
| Pregnancy | 6 | 2018 | 8105 | 0.060 |
Why?
|
| Comorbidity | 2 | 2009 | 2439 | 0.060 |
Why?
|
| Neoplasm Invasiveness | 3 | 2020 | 4071 | 0.060 |
Why?
|
| Motor Activity | 1 | 2008 | 718 | 0.060 |
Why?
|
| Cell Line, Tumor | 6 | 2014 | 14881 | 0.060 |
Why?
|
| Prostaglandin-Endoperoxide Synthases | 1 | 2005 | 232 | 0.060 |
Why?
|
| Mixed Tumor, Malignant | 1 | 2004 | 19 | 0.060 |
Why?
|
| Caregivers | 1 | 2010 | 740 | 0.060 |
Why?
|
| Vacuum | 1 | 2003 | 42 | 0.060 |
Why?
|
| Postmenopause | 2 | 2004 | 380 | 0.060 |
Why?
|
| Ultrasonography | 1 | 2011 | 1943 | 0.060 |
Why?
|
| Imatinib Mesylate | 2 | 2005 | 1690 | 0.060 |
Why?
|
| Appendiceal Neoplasms | 1 | 2006 | 251 | 0.060 |
Why?
|
| Academic Medical Centers | 2 | 2018 | 690 | 0.060 |
Why?
|
| Mesna | 1 | 2003 | 67 | 0.060 |
Why?
|
| Vulva | 1 | 2003 | 38 | 0.060 |
Why?
|
| Sexual Behavior | 2 | 2018 | 321 | 0.060 |
Why?
|
| Lactobacillus | 1 | 2023 | 59 | 0.060 |
Why?
|
| Bandages | 1 | 2003 | 80 | 0.050 |
Why?
|
| Organoplatinum Compounds | 3 | 2017 | 704 | 0.050 |
Why?
|
| Perineum | 1 | 2003 | 116 | 0.050 |
Why?
|
| Adenocarcinoma, Mucinous | 1 | 2006 | 443 | 0.050 |
Why?
|
| Patient Education as Topic | 1 | 2008 | 748 | 0.050 |
Why?
|
| Outpatients | 1 | 2006 | 469 | 0.050 |
Why?
|
| Terminally Ill | 1 | 2003 | 96 | 0.050 |
Why?
|
| Leuprolide | 1 | 2023 | 67 | 0.050 |
Why?
|
| bcl-2-Associated X Protein | 2 | 2001 | 380 | 0.050 |
Why?
|
| Chemoradiotherapy, Adjuvant | 2 | 2018 | 562 | 0.050 |
Why?
|
| Benzamides | 2 | 2005 | 1882 | 0.050 |
Why?
|
| Skin Transplantation | 1 | 2003 | 185 | 0.050 |
Why?
|
| Body Mass Index | 3 | 2020 | 2259 | 0.050 |
Why?
|
| Mucus | 1 | 2022 | 109 | 0.050 |
Why?
|
| Pyrimidines | 2 | 2005 | 3664 | 0.050 |
Why?
|
| Lung Neoplasms | 2 | 2020 | 12012 | 0.050 |
Why?
|
| Papillomavirus E7 Proteins | 1 | 2022 | 64 | 0.050 |
Why?
|
| Mothers | 1 | 2005 | 418 | 0.050 |
Why?
|
| Radiography | 1 | 2006 | 1994 | 0.050 |
Why?
|
| Lactic Acid | 1 | 2023 | 312 | 0.050 |
Why?
|
| Neoplasm Metastasis | 3 | 2018 | 5330 | 0.050 |
Why?
|
| Patient Compliance | 1 | 2006 | 682 | 0.050 |
Why?
|
| Phosphoric Monoester Hydrolases | 1 | 2002 | 265 | 0.050 |
Why?
|
| Metagenome | 1 | 2022 | 193 | 0.050 |
Why?
|
| Forkhead Box Protein L2 | 1 | 2021 | 17 | 0.050 |
Why?
|
| Flow Cytometry | 1 | 2007 | 3078 | 0.050 |
Why?
|
| Cost-Benefit Analysis | 2 | 2018 | 968 | 0.050 |
Why?
|
| Antigens, Differentiation, T-Lymphocyte | 1 | 2021 | 170 | 0.050 |
Why?
|
| Proto-Oncogene Proteins c-akt | 3 | 2016 | 2085 | 0.050 |
Why?
|
| Incidence | 2 | 2022 | 5864 | 0.050 |
Why?
|
| Proportional Hazards Models | 3 | 2016 | 5118 | 0.050 |
Why?
|
| Metabolic Networks and Pathways | 1 | 2022 | 342 | 0.050 |
Why?
|
| Neurofibromin 1 | 1 | 2021 | 84 | 0.050 |
Why?
|
| Pericardium | 1 | 2001 | 149 | 0.040 |
Why?
|
| Internship and Residency | 1 | 2011 | 1441 | 0.040 |
Why?
|
| Retinal Dehydrogenase | 1 | 2020 | 88 | 0.040 |
Why?
|
| Lectins, C-Type | 1 | 2021 | 163 | 0.040 |
Why?
|
| Counseling | 1 | 2023 | 385 | 0.040 |
Why?
|
| Life Style | 1 | 2024 | 623 | 0.040 |
Why?
|
| Human papillomavirus 16 | 1 | 2022 | 257 | 0.040 |
Why?
|
| Etoposide | 2 | 2017 | 905 | 0.040 |
Why?
|
| Administration, Cutaneous | 1 | 2020 | 145 | 0.040 |
Why?
|
| Annexin A5 | 1 | 2000 | 75 | 0.040 |
Why?
|
| ErbB Receptors | 1 | 2008 | 2383 | 0.040 |
Why?
|
| Professional-Family Relations | 1 | 2000 | 130 | 0.040 |
Why?
|
| Cell Nucleus | 2 | 2010 | 1740 | 0.040 |
Why?
|
| Biodiversity | 1 | 2020 | 93 | 0.040 |
Why?
|
| Hematopoietic Stem Cell Transplantation | 1 | 2018 | 6987 | 0.040 |
Why?
|
| Signal Transduction | 3 | 2013 | 12223 | 0.040 |
Why?
|
| Heart Neoplasms | 1 | 2001 | 216 | 0.040 |
Why?
|
| Physicians, Women | 1 | 2000 | 99 | 0.040 |
Why?
|
| In Situ Nick-End Labeling | 1 | 2000 | 449 | 0.040 |
Why?
|
| Age Factors | 2 | 2019 | 5526 | 0.040 |
Why?
|
| Algorithms | 1 | 2010 | 3925 | 0.040 |
Why?
|
| Vinblastine | 2 | 2010 | 462 | 0.040 |
Why?
|
| Hospitals, County | 1 | 2018 | 31 | 0.040 |
Why?
|
| Case-Control Studies | 2 | 2019 | 6236 | 0.040 |
Why?
|
| Pharmacy Service, Hospital | 1 | 2019 | 58 | 0.040 |
Why?
|
| Hyperplasia | 2 | 1997 | 581 | 0.040 |
Why?
|
| Hospitals, Community | 1 | 2019 | 81 | 0.040 |
Why?
|
| Appointments and Schedules | 1 | 2019 | 97 | 0.040 |
Why?
|
| Uterine Hemorrhage | 1 | 1999 | 64 | 0.040 |
Why?
|
| Ataxia Telangiectasia Mutated Proteins | 1 | 2021 | 437 | 0.040 |
Why?
|
| Fellowships and Scholarships | 1 | 2003 | 409 | 0.040 |
Why?
|
| Drug Synergism | 3 | 2008 | 1364 | 0.040 |
Why?
|
| Nursing Staff, Hospital | 1 | 2019 | 76 | 0.040 |
Why?
|
| Sexual Health | 1 | 2018 | 17 | 0.040 |
Why?
|
| Molecular Targeted Therapy | 2 | 2020 | 2400 | 0.040 |
Why?
|
| Leukopenia | 2 | 2009 | 153 | 0.040 |
Why?
|
| Transfection | 2 | 2001 | 3166 | 0.040 |
Why?
|
| Minority Groups | 1 | 2020 | 321 | 0.040 |
Why?
|
| Salpingo-oophorectomy | 1 | 2018 | 50 | 0.040 |
Why?
|
| Quinolines | 1 | 2021 | 403 | 0.040 |
Why?
|
| Students | 1 | 2020 | 330 | 0.040 |
Why?
|
| Workflow | 1 | 2019 | 291 | 0.040 |
Why?
|
| Phenylurea Compounds | 1 | 2021 | 600 | 0.040 |
Why?
|
| Cell Cycle | 2 | 2001 | 2150 | 0.040 |
Why?
|
| Wnt Signaling Pathway | 1 | 2020 | 445 | 0.040 |
Why?
|
| Diagnosis, Differential | 1 | 2006 | 4900 | 0.040 |
Why?
|
| Dactinomycin | 1 | 2017 | 163 | 0.040 |
Why?
|
| Cell Adhesion | 1 | 2000 | 1041 | 0.040 |
Why?
|
| Intercellular Signaling Peptides and Proteins | 1 | 2020 | 673 | 0.040 |
Why?
|
| Uterine Cervical Diseases | 1 | 1997 | 24 | 0.040 |
Why?
|
| Breast Neoplasms | 2 | 2017 | 16244 | 0.040 |
Why?
|
| Protein-Tyrosine Kinases | 1 | 2004 | 1842 | 0.030 |
Why?
|
| Platinum Compounds | 1 | 2017 | 129 | 0.030 |
Why?
|
| Omentum | 1 | 1997 | 107 | 0.030 |
Why?
|
| Age Distribution | 1 | 2018 | 730 | 0.030 |
Why?
|
| Fallopian Tubes | 1 | 1997 | 131 | 0.030 |
Why?
|
| Receptors, Cell Surface | 1 | 2020 | 911 | 0.030 |
Why?
|
| Parenting | 1 | 2000 | 353 | 0.030 |
Why?
|
| Lectins | 1 | 2016 | 152 | 0.030 |
Why?
|
| Ascites | 1 | 1997 | 216 | 0.030 |
Why?
|
| Cell Proliferation | 3 | 2016 | 7302 | 0.030 |
Why?
|
| Bacteria | 1 | 2021 | 652 | 0.030 |
Why?
|
| ATP-Binding Cassette Transporters | 2 | 2008 | 319 | 0.030 |
Why?
|
| Genetic Counseling | 1 | 2018 | 417 | 0.030 |
Why?
|
| Klebsiella Infections | 1 | 1996 | 62 | 0.030 |
Why?
|
| GPI-Linked Proteins | 1 | 2016 | 229 | 0.030 |
Why?
|
| Tumor Cells, Cultured | 2 | 2001 | 5804 | 0.030 |
Why?
|
| Diet | 1 | 2024 | 1489 | 0.030 |
Why?
|
| Antigens, CD | 1 | 2021 | 1436 | 0.030 |
Why?
|
| Mitogen-Activated Protein Kinase 3 | 1 | 2016 | 278 | 0.030 |
Why?
|
| CD4-Positive T-Lymphocytes | 1 | 2021 | 1054 | 0.030 |
Why?
|
| Feces | 1 | 2019 | 866 | 0.030 |
Why?
|
| Caspase 3 | 1 | 2016 | 481 | 0.030 |
Why?
|
| Pleural Effusion | 1 | 1997 | 219 | 0.030 |
Why?
|
| Chemotherapy-Induced Febrile Neutropenia | 1 | 2015 | 33 | 0.030 |
Why?
|
| RNA-Directed DNA Polymerase | 1 | 2014 | 71 | 0.030 |
Why?
|
| Waiting Lists | 1 | 2017 | 265 | 0.030 |
Why?
|
| Regression Analysis | 2 | 2011 | 1589 | 0.030 |
Why?
|
| Leptin | 1 | 2016 | 312 | 0.030 |
Why?
|
| Enzyme-Linked Immunosorbent Assay | 2 | 2008 | 1534 | 0.030 |
Why?
|
| Nutrition Surveys | 1 | 2016 | 319 | 0.030 |
Why?
|
| Hospitals | 1 | 2018 | 493 | 0.030 |
Why?
|
| Tumor Suppressor Proteins | 1 | 2002 | 1905 | 0.030 |
Why?
|
| Pemetrexed | 1 | 2014 | 100 | 0.030 |
Why?
|
| Adenoviridae | 1 | 2000 | 1514 | 0.030 |
Why?
|
| Genetic Vectors | 1 | 2000 | 1887 | 0.030 |
Why?
|
| Glutamates | 1 | 2014 | 134 | 0.030 |
Why?
|
| Neutropenia | 2 | 2009 | 1001 | 0.030 |
Why?
|
| Candidiasis | 1 | 1996 | 281 | 0.030 |
Why?
|
| Proto-Oncogene Proteins | 2 | 2001 | 2624 | 0.030 |
Why?
|
| Catheterization | 1 | 1996 | 425 | 0.030 |
Why?
|
| Membrane Proteins | 2 | 2020 | 2975 | 0.030 |
Why?
|
| Repressor Proteins | 1 | 2022 | 1730 | 0.030 |
Why?
|
| Guanine | 1 | 2014 | 157 | 0.030 |
Why?
|
| B7-H1 Antigen | 1 | 2021 | 1075 | 0.030 |
Why?
|
| Remission Induction | 1 | 2020 | 3645 | 0.030 |
Why?
|
| Adaptor Proteins, Signal Transducing | 1 | 2020 | 1483 | 0.030 |
Why?
|
| AMP-Activated Protein Kinases | 1 | 2016 | 409 | 0.030 |
Why?
|
| Adjuvants, Pharmaceutic | 1 | 2013 | 20 | 0.030 |
Why?
|
| Clinical Trials as Topic | 2 | 2016 | 3856 | 0.030 |
Why?
|
| Biopsy, Needle | 1 | 2018 | 1402 | 0.030 |
Why?
|
| Insulin-Like Growth Factor I | 1 | 2016 | 641 | 0.030 |
Why?
|
| Methotrexate | 1 | 2017 | 1033 | 0.030 |
Why?
|
| Streptococcal Infections | 1 | 1996 | 313 | 0.030 |
Why?
|
| Receptor, ErbB-2 | 1 | 2003 | 2649 | 0.030 |
Why?
|
| Electrosurgery | 1 | 2013 | 27 | 0.030 |
Why?
|
| SEER Program | 1 | 2017 | 1047 | 0.030 |
Why?
|
| Drug Screening Assays, Antitumor | 2 | 2006 | 569 | 0.030 |
Why?
|
| Gene Expression Profiling | 1 | 2005 | 5187 | 0.030 |
Why?
|
| Europe | 1 | 2015 | 660 | 0.030 |
Why?
|
| Patient Participation | 1 | 2017 | 452 | 0.030 |
Why?
|
| Odds Ratio | 1 | 2018 | 2335 | 0.030 |
Why?
|
| Vincristine | 1 | 2017 | 1572 | 0.030 |
Why?
|
| Electroencephalography | 1 | 2018 | 996 | 0.030 |
Why?
|
| Salpingectomy | 1 | 2013 | 46 | 0.030 |
Why?
|
| Transplantation, Autologous | 1 | 2018 | 2048 | 0.030 |
Why?
|
| Kidney Neoplasms | 1 | 2006 | 3153 | 0.030 |
Why?
|
| Cytotoxicity, Immunologic | 1 | 2014 | 683 | 0.030 |
Why?
|
| Fluorouracil | 2 | 2007 | 1988 | 0.020 |
Why?
|
| Logistic Models | 1 | 2019 | 3469 | 0.020 |
Why?
|
| Drug Resistance, Neoplasm | 4 | 2008 | 5421 | 0.020 |
Why?
|
| Reverse Transcriptase Polymerase Chain Reaction | 2 | 2008 | 3651 | 0.020 |
Why?
|
| Gastrointestinal Neoplasms | 1 | 2017 | 624 | 0.020 |
Why?
|
| Human Papillomavirus Recombinant Vaccine Quadrivalent, Types 6, 11, 16, 18 | 1 | 2011 | 4 | 0.020 |
Why?
|
| Biomarkers | 2 | 2020 | 5115 | 0.020 |
Why?
|
| Transplantation, Homologous | 1 | 2018 | 3036 | 0.020 |
Why?
|
| Precancerous Conditions | 1 | 2018 | 1065 | 0.020 |
Why?
|
| Cognition | 1 | 2017 | 984 | 0.020 |
Why?
|
| Cryosurgery | 1 | 2013 | 186 | 0.020 |
Why?
|
| Biopsy | 1 | 1999 | 3544 | 0.020 |
Why?
|
| Phosphoproteins | 1 | 2016 | 1230 | 0.020 |
Why?
|
| Parity | 1 | 2011 | 136 | 0.020 |
Why?
|
| Insulin | 1 | 2016 | 1508 | 0.020 |
Why?
|
| Mutation | 2 | 2021 | 15944 | 0.020 |
Why?
|
| Electronic Health Records | 1 | 2018 | 971 | 0.020 |
Why?
|
| Vaginal Smears | 1 | 2011 | 183 | 0.020 |
Why?
|
| Pain Measurement | 1 | 2014 | 1017 | 0.020 |
Why?
|
| Phosphatidylinositol 3-Kinases | 1 | 2016 | 1720 | 0.020 |
Why?
|
| Gastrointestinal Diseases | 1 | 2015 | 617 | 0.020 |
Why?
|
| Lymphocyte Activation | 1 | 2014 | 1728 | 0.020 |
Why?
|
| Cyclophosphamide | 1 | 2017 | 3231 | 0.020 |
Why?
|
| Neoplasms, Second Primary | 1 | 2018 | 1388 | 0.020 |
Why?
|
| Retreatment | 1 | 2010 | 448 | 0.020 |
Why?
|
| T-Lymphocytes | 1 | 2022 | 3947 | 0.020 |
Why?
|
| Anemia | 1 | 2015 | 730 | 0.020 |
Why?
|
| Gene Expression Regulation, Neoplastic | 2 | 2008 | 9101 | 0.020 |
Why?
|
| Genotype | 1 | 2016 | 4267 | 0.020 |
Why?
|
| Everolimus | 1 | 2010 | 438 | 0.020 |
Why?
|
| Antigens, Neoplasm | 1 | 2014 | 1590 | 0.020 |
Why?
|
| Animals | 1 | 2013 | 62822 | 0.020 |
Why?
|
| Solutions | 1 | 2007 | 109 | 0.020 |
Why?
|
| Indicators and Reagents | 1 | 2007 | 140 | 0.020 |
Why?
|
| Cyclin-Dependent Kinase Inhibitor p27 | 1 | 2008 | 300 | 0.020 |
Why?
|
| Carcinoma, Adenosquamous | 1 | 2007 | 107 | 0.020 |
Why?
|
| Prenatal Diagnosis | 1 | 2011 | 609 | 0.020 |
Why?
|
| Radiopharmaceuticals | 1 | 2012 | 1338 | 0.020 |
Why?
|
| Graft vs Host Disease | 1 | 2018 | 2804 | 0.020 |
Why?
|
| Neoplasm, Residual | 1 | 2013 | 1741 | 0.020 |
Why?
|
| Needs Assessment | 1 | 2008 | 237 | 0.020 |
Why?
|
| Administration, Oral | 1 | 2010 | 1622 | 0.020 |
Why?
|
| Risk | 1 | 2010 | 1950 | 0.020 |
Why?
|
| Pregnancy Complications | 1 | 2011 | 560 | 0.020 |
Why?
|
| Drug Interactions | 1 | 2007 | 585 | 0.020 |
Why?
|
| Cell Growth Processes | 1 | 2006 | 340 | 0.020 |
Why?
|
| Nuclear Proteins | 1 | 1997 | 3472 | 0.020 |
Why?
|
| Risk Assessment | 1 | 2018 | 6885 | 0.020 |
Why?
|
| Medical Records | 1 | 2006 | 447 | 0.020 |
Why?
|
| RNA, Neoplasm | 1 | 2007 | 810 | 0.020 |
Why?
|
| Brain | 1 | 2018 | 4257 | 0.010 |
Why?
|
| Receptors, Platelet-Derived Growth Factor | 1 | 2004 | 109 | 0.010 |
Why?
|
| Injections, Intraperitoneal | 1 | 2004 | 210 | 0.010 |
Why?
|
| Capecitabine | 1 | 2005 | 390 | 0.010 |
Why?
|
| Paraffin Embedding | 1 | 2004 | 229 | 0.010 |
Why?
|
| Glutathione | 1 | 2006 | 376 | 0.010 |
Why?
|
| Bleomycin | 1 | 2005 | 482 | 0.010 |
Why?
|
| Adenoviruses, Human | 1 | 2004 | 191 | 0.010 |
Why?
|
| Delivery of Health Care | 1 | 2011 | 878 | 0.010 |
Why?
|
| Anti-Bacterial Agents | 1 | 1996 | 3176 | 0.010 |
Why?
|
| Proteomics | 1 | 2010 | 1437 | 0.010 |
Why?
|
| RNA | 1 | 2007 | 1072 | 0.010 |
Why?
|
| Diabetes Mellitus | 1 | 2011 | 1076 | 0.010 |
Why?
|
| Blotting, Western | 1 | 2007 | 3646 | 0.010 |
Why?
|
| Cell Survival | 1 | 2007 | 3074 | 0.010 |
Why?
|
| Multivariate Analysis | 1 | 2007 | 4352 | 0.010 |
Why?
|
| Job Satisfaction | 1 | 2000 | 124 | 0.010 |
Why?
|
| Analysis of Variance | 1 | 2004 | 2337 | 0.010 |
Why?
|
| Radiotherapy | 1 | 2006 | 1860 | 0.010 |
Why?
|
| Uterine Cervicitis | 1 | 1997 | 7 | 0.010 |
Why?
|
| Image Cytometry | 1 | 1997 | 46 | 0.010 |
Why?
|
| PTEN Phosphohydrolase | 1 | 2002 | 1014 | 0.010 |
Why?
|
| Dose-Response Relationship, Drug | 1 | 2005 | 5107 | 0.010 |
Why?
|
| Phosphorylation | 1 | 2004 | 4984 | 0.010 |
Why?
|
| Antigens, Nuclear | 1 | 1997 | 128 | 0.010 |
Why?
|
| Radiation Injuries | 1 | 2004 | 1472 | 0.010 |
Why?
|
| Autoantigens | 1 | 1997 | 250 | 0.010 |
Why?
|
| Postoperative Complications | 1 | 2004 | 5693 | 0.000 |
Why?
|
| Liver Neoplasms | 1 | 2001 | 4811 | 0.000 |
Why?
|
| Antibodies, Monoclonal | 1 | 1997 | 4496 | 0.000 |
Why?
|